STOCK TITAN
  1. Home
  2. News
  3. VVOS

Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.

Vivos Therapeutics, Inc. (symbol: VVOS) is a leading medical technology company dedicated to providing innovative solutions for patients suffering from sleep disordered breathing (SDB), particularly mild-to-moderate obstructive sleep apnea (OSA). The company specializes in the development and commercialization of proprietary treatment protocols and customized oral appliances, known collectively as the Vivos System. This non-surgical, non-invasive, and non-pharmaceutical system is designed to address craniofacial and anatomical anomalies associated with OSA, offering a cost-effective alternative to traditional treatments.

The Vivos System combines the expertise of specially trained dentists and medical professionals to deliver comprehensive care. Through its Vivos Integrated Healthcare Network, the company enables healthcare providers, including general dentists, medical doctors, myofunctional therapists, and chiropractors, to offer targeted therapies for SDB. Additionally, Vivos licenses its intellectual property to third-party manufacturers to fabricate these advanced appliance devices, expanding its reach and impact.

Recent developments at Vivos Therapeutics highlight the company's commitment to improving patient outcomes. The favorable update to United Healthcare's medical policy now endorses oral appliance therapies, potentially increasing the adoption of Vivos devices. Furthermore, the recall of numerous CPAP devices by ResMed and Philips Respironics presents a significant revenue opportunity for Vivos.

The company has also achieved a significant milestone with the introduction of the first Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults. This breakthrough enhances the accessibility of effective OSA treatment to a broader patient population.

Vivos Therapeutics continues to position itself as a pioneer in the medical technology space, driven by its mission to improve the quality of life for patients with sleep-disordered breathing. Stay informed about Vivos Therapeutics' latest news and developments to understand the dynamic landscape of this innovative company.

News

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) reported Q1 2024 financial results, highlighting a 22% reduction in operating expenses and a gross margin of 57%. Revenue for Q1 2024 was $3.4 million, down from $3.8 million in Q1 2023, due to lower VIP enrollments and CARE appliance revenue. However, revenue from pediatric and lifeline appliances and home sleep testing services increased. Gross profit was $1.9 million. Despite revenue decline, cost-cutting initiatives reduced operating loss by 24% year-over-year. Cash and cash equivalents were $2.6 million. Over 42,600 patients have been treated with Vivos' devices, and regulatory approvals for Medicare reimbursement were obtained in April 2024. The company expects positive cash flow by end-2024, driven by new strategic revenue initiatives and improved market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.45%
Tags
earnings
-
News

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS), a key player in medical devices for sleep-related breathing disorders, will release its Q1 2024 financial results today, May 14, 2024, after market close. The company will hold a conference call at 5:00 p.m. ET to discuss financial results and recent milestones. Investors can join the call via provided phone numbers or access a live webcast on the company's website. A replay of the call will be available until May 28, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.88%
Tags
earnings
-
News

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Rhea-AI Summary
Vivos Therapeutics, Inc. receives Medicare approval for its CARE oral medical devices, marking a significant milestone in the treatment of obstructive sleep apnea in adults. The approval allows for Medicare reimbursement, providing coverage to millions of beneficiaries and offering an alternative to CPAP therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.08%
Tags
none
News

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Rhea-AI Summary
Vivos Therapeutics reports positive business momentum and sales pipeline growth following FDA 510(k) clearance for oral medical devices to treat severe obstructive sleep apnea. The company's annual operating expenses decreased by 27% due to successful cost-cutting initiatives. Vivos aims for cash flow positive operations by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.23%
Tags
earnings
-
News

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Rhea-AI Summary
Vivos Therapeutics, Inc. announces the release of its fourth quarter and full year 2023 financial results, along with plans for a conference call to discuss recent milestones and developments in the field of sleep-related breathing disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
earnings
-
News

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

Rhea-AI Summary
Vivos Therapeutics, Inc. announces the immediate exercise of a common stock purchase warrant by an institutional investor, resulting in gross proceeds of approximately $4.0 million. The investor will purchase 980,393 shares of Vivos common stock at a revised exercise price of $4.02 per share. In return, Vivos will issue two new unregistered warrants to the investor, each allowing the purchase of 735,296 shares at an exercise price of $5.05 per share. The transaction is expected to close by February 20, 2024, with net proceeds intended for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
News

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Rhea-AI Summary
Vivos Therapeutics, Inc. (VVOS) highlights favorable market developments, including United Healthcare's updated medical policy and recent recalls of CPAP devices by ResMed and Philips Respironics, creating significant revenue opportunities for the company's oral appliance therapies. The FDA granted a 510(k) clearance to Vivos CARE appliances to treat moderate and severe OSA in adults. Vivos is well-positioned to assist patients and providers affected by the discontinuation of CPAP devices by Philips Respironics, offering a safe and effective alternative treatment option. United Healthcare's revised OSA medical treatment policy further supports the use of oral appliance therapy, providing a substantial opportunity for Vivos to expand its user base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
-
News

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA

Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced a significant increase in new dentist inquiries, VIP enrollment contracts, and CARE oral medical device orders following the FDA clearance of its oral medical devices to treat severe obstructive sleep apnea (OSA). The company reported a 600% rise in new dentist inquiries, 38% sequential increase in signed VIP enrollment contracts, and a 26% increase in CARE appliance orders. Vivos expects these positive metrics to drive revenue growth in 2024, with a 53% increase in sales of pediatric guided growth and development appliances. Toothpillow, a key dental service organization partner, also experienced a surge in interest and new patient inquiries, indicating a growing market for Vivos products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
clinical trial
-
News

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Rhea-AI Summary
Vivos Therapeutics, Inc. (VVOS) has received FDA 510(k) clearance for its oral device to treat severe OSA, leading to the 'Empowering Women to Champion Airway' event to unite influential women in medicine and dentistry. The event aims to foster collaboration and empower women to drive positive transformations in healthcare. Vivos' CARE appliances have been granted FDA clearance to treat moderate and severe OSA in adults, providing a new alternative to CPAP or surgery. The company is hosting a conference to enhance collaboration between medical and dental professionals to provide optimal treatment solutions for patients with sleep and breathing disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.44%
Tags
none
News

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Rhea-AI Summary
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has received FDA clearance for treating severe obstructive sleep apnea (OSA) in adults using the Vivos' removable CARE oral appliances, marking the first time the FDA has approved an oral appliance to treat moderate and severe OSA in adults. The statistically significant data submitted to the FDA from 73 severe OSA patients showed that 80% of patients experienced an improvement of at least 1 classification or at least a 50% improvement in the Apnea Hypopnea Index (AHI), and 97% of patients improved or stayed the same, with an average treatment time of just 9.7 months. The company believes this unprecedented decision by the FDA will generate broader acceptance throughout the medical community for Vivos treatment options, leading to the potential for higher patient referrals and case starts as well as collaboration with medical professionals, enhancing their value proposition to third-party distribution partners such as durable medical equipment (DME) companies, and clearing the way for greater reimbursement levels from medical insurance payors and Medicare, favorably impacting their ability to grow revenues in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
833.94%
Tags
clinical trial

FAQ

What is the current stock price of Vivos Therapeutics (VVOS)?

The current stock price of Vivos Therapeutics (VVOS) is $5.12 as of December 23, 2024.

What is the market cap of Vivos Therapeutics (VVOS)?

The market cap of Vivos Therapeutics (VVOS) is approximately 22.0M.

What does Vivos Therapeutics, Inc. specialize in?

Vivos Therapeutics specializes in the development and commercialization of technology solutions for patients with sleep disordered breathing, including mild-to-moderate obstructive sleep apnea.

What is the Vivos System?

The Vivos System is a non-surgical, non-invasive treatment for mild-to-moderate obstructive sleep apnea, involving customized oral appliances and proprietary treatment protocols.

Who can benefit from Vivos Therapeutics' solutions?

Patients with mild-to-moderate obstructive sleep apnea (OSA) and related sleep disordered breathing conditions can benefit from Vivos Therapeutics' solutions.

How does Vivos Therapeutics collaborate with healthcare providers?

Vivos Therapeutics collaborates with healthcare providers through its Vivos Integrated Healthcare Network, enabling dentists, medical doctors, and other professionals to offer targeted treatments.

What are some recent achievements of Vivos Therapeutics?

Recent achievements include the favorable update to United Healthcare's policy supporting oral appliance therapies and the introduction of Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea.

What opportunities have arisen from the recall of CPAP devices?

The recall of CPAP devices by ResMed and Philips Respironics has created significant revenue opportunities for Vivos Therapeutics' oral appliance devices.

How does Vivos Therapeutics manufacture its oral appliances?

Vivos Therapeutics licenses its intellectual property to third-party manufacturers who fabricate the appliance devices for healthcare professionals.

What makes the Vivos System unique?

The Vivos System is unique due to its non-surgical, non-invasive, and non-pharmaceutical approach, offering a cost-effective solution for treating mild-to-moderate obstructive sleep apnea.

Who are the target customers for Vivos Therapeutics?

Target customers include general dentists, medical doctors, myofunctional therapists, chiropractors, and other healthcare providers involved in treating sleep disordered breathing.

What is the mission of Vivos Therapeutics?

The mission of Vivos Therapeutics is to improve the quality of life for patients suffering from sleep disordered breathing through innovative and effective treatment solutions.

Stock VVOS logo
Vivos Therapeutics, Inc.

Nasdaq:VVOS

VVOS Rankings

#5273 Ranked by Market Cap
N/A Ranked by Dividends

VVOS Stock Data

21.95M
4.76M
1.51%
13.72%
2%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
LITTLETON